Sosei Heptares Partner Pfizer Progresses Its Oral Glp 1 Receptor Agonist Pf 07081532 Into Phase 2 Clinical Trials For Treating Type 2 Diabetes And Obesity
Sosei Heptares Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity
PF-07081532 is the first clinical candidate from multi-target drug discovery collaboration to advance into Phase 2 trials
Dosing of first subject in Phase 2 trial by Pfizer triggers payment of US$10 million to Sosei Heptares
Sosei Group Corporation the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, has been notified by Pfizer that the first subject in a Phase 2 clinical trial has been dosed with Pfizer
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!